Mycophenolate Mofetil for Autoimmune Hepatitis: A Single Practice Experience

  • David C. WolfEmail author
  • Lizza Bojito
  • Marcelo Facciuto
  • Edward Lebovics
Original Article


Autoimmune hepatitis (AIH) is refractory to standard therapy with prednisone and azathioprine in 20% of patients. Investigators are exploring alternative immunosuppressant treatments, including mycophenolate mofetil (MMF). We assessed the outcome of MMF therapy in patients with AIH and related disorders. A retrospective analysis was performed in 16 patients with AIH, immune cholangitis, and overlap syndromes between AIH, primary biliary cirrhosis, and primary sclerosing cholangitis. MMF was used in lieu of azathioprine on account of patients’ intolerance to azathioprine, disease that was refractory to prednisone plus azathioprine, or the perceived potency of MMF. With initiation of MMF, median ALT decreased from 81.5 U/l to 42.5 U/l (P = 0.03). Median prednisone dose decreased from 10 mg to 2.5 mg (P = 0.01). Prednisone was completely withdrawn in three patients. Five of 16 patients (31%) achieved biochemical remission, defined as a reduction in ALT from greater than to less than twice normal. Seven additional patients (44%) were maintained in biochemical remission. Two patients had an incomplete response to MMF and two patients experienced treatment failure. MMF was tolerated well in all but one patient, who discontinued the drug on account of paresthesias. MMF may be a safe and effective alternative to azathioprine in patients with AIH and related disorders.


Mycophenolate mofetil Autoimmune hepatitis Immunosuppression 



Autoimmune hepatitis


Alanine aminotransferase


Immunoglobulin G


Mycophenolate mofetil


Primary biliary cirrhosis


Primary sclerosing cholangitis


  1. 1.
    Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol. 2000;33:371–375. doi: 10.1016/S0168-8278(00)80271-8.CrossRefPubMedGoogle Scholar
  2. 2.
    Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate moftil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol. 2004;18:321–326.PubMedGoogle Scholar
  3. 3.
    Chatur N, Ramji A, Bain VG, et al. Transplant immunosupressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723–727. doi: 10.1111/j.1478-3231.2005.01107.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol. 2005;39:819–825. doi: 10.1097/01.mcg.0000177260.72692.e8.CrossRefPubMedGoogle Scholar
  5. 5.
    Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol. 2007;5:799–8082. doi: 10.1016/j.cgh.2007.02.030.CrossRefPubMedGoogle Scholar
  6. 6.
    Czaja AJ, Freese DK. AASLD practice guidelines: diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497. doi: 10.1053/jhep.2002.34944.CrossRefPubMedGoogle Scholar
  7. 7.
    Chazouilleres O, Wendum D, Serfaty L, Rosmordgue O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006;44:400–406. doi: 10.1016/j.jhep.2005.10.017.CrossRefPubMedGoogle Scholar
  8. 8.
    Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–1522. doi: 10.1111/j.1572-0241.2005.41841.x.CrossRefPubMedGoogle Scholar
  9. 9.
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.PubMedGoogle Scholar
  10. 10.
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737. doi: 10.1016/S0140-6736(73)92125-9.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med. 1995;333:958–963. doi: 10.1056/NEJM199510123331502.CrossRefPubMedGoogle Scholar
  12. 12.
    Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927–934. doi: 10.1111/j.1478-3231.2005.01122.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006;12:1362–1366.PubMedGoogle Scholar
  14. 14.
    Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241–248. doi: 10.1111/j.1572-0241.1999.00807.x.CrossRefPubMedGoogle Scholar
  15. 15.
    Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2007;44:18–19.CrossRefGoogle Scholar
  16. 16.
    Larsen FS, Vainer B, Eefsen M, Bjjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232–3236.PubMedGoogle Scholar
  17. 17.
    Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl. 2005;11:750–759. doi: 10.1002/lt.20453.CrossRefPubMedGoogle Scholar
  18. 18.
    United States Food and Drug Administration. MedWatch. Posted 29 October 2007. Accessed 19 November 2008.

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David C. Wolf
    • 1
    Email author
  • Lizza Bojito
    • 1
  • Marcelo Facciuto
    • 2
  • Edward Lebovics
    • 1
  1. 1.Division of Gastroenterology and Hepatobiliary DiseasesNew York Medical CollegeValhallaUSA
  2. 2.Department of SurgeryNew York Medical CollegeValhallaUSA

Personalised recommendations